510-P: Serum Mac-2 Binding Protein Is Associated with Diabetic Micro- and Macroangiopathy in People with Type 2 Diabetes

Abstract

A close relationship between type 2 diabetes and nonalcoholic fatty liver disease, including liver fibrosis, has been reported. Mac-2 binding protein glycosylation isomer (M2BPGi) is reported as a non-invasive new serological glyco-biomarker for liver fibrosis. The purpose of this cross-sectional study was to investigate the association between serum M2BPGi levels and diabetic complications in people with type 2 diabetes. Serum M2BPGi levels were measured in terms of cut-off index (C.O.I.) units. Urinary albumin excretion (UAE) was calculated and nephropathy was graded as normo-, micro-, or macroalbuminuria. Retinopathy was divided into three groups: no- (NDR), simple- (SDR), or proliferative diabetic retinopathy (PDR). Mean age for 363 people (212 males) was 66.4 (10.6) years, the median M2BPGi level was 0.77 (0.57-1.04) C.O.I., and the median UAE was 22 (9-82.1) mg/g Cr. Serum M2BPGi level was increased with levels of diabetic microangiopathy. Furthermore, the M2BPGi levels in people with a history of cardiovascular diseases were higher than that in people without (0.82 [0.65-1.22] vs. 0.76 [0.55-1.03] C.O.I., p = 0.019). The logarithm of M2BPGi was associated with the logarithm of UAE after adjusting for covariates (β = 0.107, p = 0.031). This study reveals a close association between serum M2BPGi levels and diabetic micro- and macroangiopathy in people with type 2 diabetes. Disclosure Y. Hashimoto: None. M. Hamaguchi: None. M. Fukui: None.